How Eisai Hopes To Expand In India
Japan's Eisai appears set for a significant step up in product introductions in India. Improving access to these medicines for patients in the largely self-pay market is at the fulcrum of its strategy, Dr Sanjit Singh Lamba, managing director of Eisai Pharmaceuticals India Pvt Ltd, tells Scrip. Newer options like a second brand approach may also be evaluated for certain new products to expand access and availability across the country.
You may also be interested in...
Entrepreneurship Beckons As Eisai India Chief Departs
Eisai Pharmaceuticals India's managing director has left the company and plans to start his own venture.
Eisai-Mylan Tango for Second Halaven Brand In India But Eyes On Pricing, Generics
Eisai has struck a deal with Mylan for a second brand of Halaven in India, joining a growing list of foreign firms deploying this approach to expand access to novel therapies in the country amid emerging competition.
Can Emcure’s Cut-Price Eribulin Dull Halaven In India?
Emcure has launched a generic version of Eisai’s cancer drug Halaven on the Indian market at a sharp 40% discount to the innovator product, and hopes to expand patient access significantly.